LSA
BPMC

Leonteq Securities AG’s Blueprint Medicines BPMC Stock Holding History

Leonteq Securities AG’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12
Closed -$1.54K – 1330
2025
Q2 		$1.54K Sell
12
-413
-97% -$42.9K ﹤0.01% 1186
2025
Q1 		$37.6K Sell
425
-292
-41% -$28.5K ﹤0.01% 876
2024
Q4 		$62.5K Buy
+717
New +$65.7K ﹤0.01% 786
2023
Q1 		– Sell
-277
Closed -$12.1K – 1221
2022
Q4 		$12.1K Hold
277
– – ﹤0.01% 1030
2022
Q3 		$18.3K Sell
277
-100
-27% -$6.42K ﹤0.01% 966
2022
Q2 		$19K Sell
377
-850
-69% -$49.8K ﹤0.01% 980
2022
Q1 		$78.4K Buy
1,227
+750
+157% +$53.8K ﹤0.01% 778
2021
Q4 		$51.1K Buy
477
+200
+72% +$20.9K ﹤0.01% 904
2021
Q3 		$28.5K Hold
277
– – ﹤0.01% 922
2021
Q2 		$24.4K Hold
277
– – ﹤0.01% 922
2021
Q1 		$26.9K Hold
277
– – ﹤0.01% 850
2020
Q4 		$31.1K Buy
+277
New +$29.2K ﹤0.01% 855

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Leonteq Securities AG's BPMC Position: Q3 2025 in Review

Leonteq Securities AG sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 12 shares — an estimated $1.54K sold.

Leonteq Securities AG first reported a position in BPMC in Q4 2020 and held it in 12 quarters. The position peaked at $78.4K in Q1 2022. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Leonteq Securities AG reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Leonteq Securities AG sold 12 Blueprint Medicines shares in Q3 2025, an estimated $1.54K.
  • Leonteq Securities AG first reported a position in Blueprint Medicines in Q4 2020 and held it in 12 quarters.
  • Leonteq Securities AG's Blueprint Medicines position peaked at $78.4K in Q1 2022.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Leonteq Securities AG's 13F filing for Q3 2025, filed 17 Feb 2026.